Augmenting Immunotherapy
Pioneering the development of integrin-targeted agonists to improve cancer immunotherapies for solid tumors and hematologic malignancies
Our Lead Molecules
Alintegimod
Overcoming aPD-1 resistance in solid tumors
Currently undergoing a Phase Ib/IIa clinical trial, alintegimod is designed to be used in combination with immune checkpoint inhibitors to safely overcome resistance to aPD-1 drugs. Learn more…
7HP935
For safer and better cell and gene therapies
Currently undergoing IND-enabling studies, 7HP935 may improve the effectiveness of CD34+ cell-based therapies for the treatment of acute leukemias and genetic disorders of the bone marrow. Learn more…
Over $34 million in grants awarded by NIH institutions and CPRIT
Get in touch!
2450 Holcombe Blvd., Suite J
Houston, TX 77021